CONCLUSIONS: Jamaican breast cancer patients exhibit a distinctive molecular profile with a high prevalence of both triple-negative (27%) and HER2 + (25%) disease, which likely contributes to poor outcomes in this population. This evidence concerns the gene ERBB2 and breast cancer.